SK Bio-Pharmaceuticals Announces a Strategic Alliance for Innovative Drug Development With Chinese Biopharmaceutical Companies

Published: Mar 28, 2013

SEOUL, South Korea--(BUSINESS WIRE)--The South Korean pharmaceutical company, SK Biopharmaceuticals, announced that they entered into a collaboration agreement with PKU International HealthCare Group, China, and Shanghai Medicilon, China, for its novel new small molecule SKL-PSY that is being developed for the treatment of depression and bipolar disorder. SK Biopharmaceuticals and Shanghai Medicilon have been conducting various preclinical experiments for SKL-PSY since 2011. When its preclinical development has been successfully completed through the efforts of Medicilon CRO services, they will start clinical development with the newly-joined partners, Southwest Synthetic Pharmaceuticals and PKUCare Pharmaceutical R&D Center, both of which are subsidiaries of PKU International HealthCare Group.

Back to news